On Invalid Date, Royalty Pharma (NASDAQ: RPRX) reported Q2 2023 earnings per share (EPS) of $0.51, up 27.14% year over year. Total Royalty Pharma earnings for the quarter were $227.63 million. In the same quarter last year, Royalty Pharma's earnings per share (EPS) was $0.70.
As of Q3 2023, Royalty Pharma's earnings has grown -48.11% year over year. This is 56.93 percentage points lower than the US Biotechnology industry earnings growth rate of 8.82%. Royalty Pharma's earnings in the past year totalled $254.95 million.
What is RPRX's earnings date?
Royalty Pharma's earnings date is Invalid Date. Add RPRX to your watchlist to be reminded of RPRX's next earnings announcement.
What was RPRX's revenue last quarter?
On Invalid Date, Royalty Pharma (NASDAQ: RPRX) reported Q2 2023 revenue of $538.20 million up 0.42% year over year. In the same quarter last year, Royalty Pharma's revenue was $535.96 million.
What was RPRX's revenue growth in the past year?
As of Q3 2023, Royalty Pharma's revenue has grown 4.51% year over year. This is 96.23 percentage points lower than the US Biotechnology industry revenue growth rate of 100.74%. Royalty Pharma's revenue in the past year totalled $2.36 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.